Barinthus Biotherapeutics Plc ADR (BRNS)

$1.05 0.00 (N/A)
Market Cap 44.79M
Revenue (ttm) 14.97M
Net Income (ttm) -61.07M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -407.95%
Debt to Equity Ratio 0.00
Volume 53,400
Avg Vol 1,561,652
Day's Range N/A - N/A
Shares Out 40.72M
Stochastic %K 7%
Beta -0.75
Analysts Strong Sell
Price Target $5.33

Company Profile

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapeutic drug candidates for treating auto-immune and inflammatory diseases. Its lead candidate is VTP-1000, which is in Phase 1 clinical trial to restore immune non-responsiveness to gluten in patients with celiac disease. The company is also developing VTP-300, an immunotherapeutic targeting chronic hepatitis B virus infection; VTP-200, a potential non-invasive treatment for persistent hig...

Industry: Biotechnology
Sector: Healthcare
Phone: 44 1865 818 808
Address:
Zeus Building, Unit 6-10 Rutherford Avenue Harwell, Didcot, United Kingdom
skyrockets_Inc
skyrockets_Inc Sep. 16 at 6:22 PM
$BRNS Considering they have cash value of $2/share and several promising assets I'd say these levels are a GIFT. I'm adding more and more daily.
0 · Reply
andrewzoo
andrewzoo Sep. 16 at 5:05 PM
$BRNS Add at $1?
0 · Reply
DocPharm
DocPharm Sep. 11 at 4:35 PM
$BRNS adding
1 · Reply
Alorenz94
Alorenz94 Sep. 10 at 4:36 PM
$BRNS more volume today
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 8:00 AM
$BRNS Brilliant piece that captures BRNS's situation perfectly. So if you want to update your understanding of BRNS or get to know BRNS better, this is essential reading. https://beyondspx.com/quote/BRNS/analysis/barinthus-bio-s-strategic-pivot-unlocking-immune-tolerance-potential-nasdaq-brns
0 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 9 at 4:54 PM
$BRNS
0 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 9 at 2:56 PM
$BRNS volume is still abnormally high for this stock. I still maintain something is going on behind the scenes and we are going to get a large upward movement soon!
1 · Reply
Alorenz94
Alorenz94 Sep. 9 at 12:25 PM
$BRNS char gbt commentary:
0 · Reply
DocPharm
DocPharm Sep. 8 at 6:27 PM
$BRNS adding a few over the next few days
1 · Reply
Alorenz94
Alorenz94 Sep. 5 at 8:11 PM
$BRNS somebody just bought 10-20k shares are the close
0 · Reply
Latest News on BRNS
Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

Jun 9, 2025, 9:00 AM EDT - 3 months ago

Barinthus Biotherapeutics' CEO Bill Enright to Present at the Investor Summit Virtual on June 10, 2025

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Mar 20, 2025, 7:22 AM EDT - 6 months ago

Barinthus Bio Reports Full Year 2024 Financial Results and Updates on Corporate Developments

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

Mar 6, 2025, 8:30 AM EST - 6 months ago

Barinthus Biotherapeutics plc to Present at the Investor Summit Virtual on March 11

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Jan 10, 2025, 8:00 AM EST - 8 months ago

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Nov 25, 2024, 4:01 PM EST - 10 months ago

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Nov 15, 2024, 11:02 AM EST - 10 months ago

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Nov 15, 2024, 11:01 AM EST - 10 months ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Nov 6, 2024, 8:00 AM EST - 11 months ago

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Jun 12, 2024, 4:01 PM EDT - 1 year ago

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Jun 6, 2024, 11:15 AM EDT - 1 year ago

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

May 13, 2024, 8:00 AM EDT - 1 year ago

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

May 1, 2024, 7:00 AM EDT - 1 year ago

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Apr 18, 2024, 4:10 PM EDT - 1 year ago

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Mar 20, 2024, 8:15 AM EDT - 1 year ago

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Jan 5, 2024, 4:01 PM EST - 1 year ago

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

New partnership aims to advance vaccine against MERS coronavirus

Dec 21, 2023, 7:31 AM EST - 1 year ago

New partnership aims to advance vaccine against MERS coronavirus

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Nov 9, 2023, 4:24 PM EST - 2 years ago

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Nov 9, 2023, 4:01 PM EST - 2 years ago

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Nov 6, 2023, 9:05 AM EST - 2 years ago

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Sep 13, 2023, 8:00 AM EDT - 2 years ago

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Jun 21, 2023, 9:03 AM EDT - 2 years ago

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Jun 12, 2023, 7:30 AM EDT - 2 years ago

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 12, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Mar 28, 2023, 8:00 AM EDT - 2 years ago

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Mar 24, 2023, 8:06 AM EDT - 2 years ago

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Nov 21, 2022, 10:31 AM EST - 3 years ago

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Nov 10, 2022, 4:30 PM EST - 3 years ago

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Nov 7, 2022, 8:00 AM EST - 3 years ago

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Nov 2, 2022, 8:00 AM EDT - 3 years ago

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Oct 3, 2022, 4:30 PM EDT - 3 years ago

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 20, 2022, 4:30 PM EDT - 3 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Vaccitech to Present at Upcoming September Investors Conferences

Sep 7, 2022, 4:01 PM EDT - 3 years ago

Vaccitech to Present at Upcoming September Investors Conferences

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Aug 9, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Jul 7, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Jun 22, 2022, 1:48 PM EDT - 3 years ago

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Jun 22, 2022, 6:00 AM EDT - 3 years ago

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech to Present at the Jefferies Healthcare Conference

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Jun 6, 2022, 7:32 AM EDT - 3 years ago

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

May 20, 2022, 11:30 AM EDT - 3 years ago

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

May 11, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Apr 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 3, 2022, 7:57 PM EDT - 3 years ago

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Mar 25, 2022, 7:15 AM EDT - 3 years ago

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Mar 7, 2022, 8:00 AM EST - 3 years ago

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Jan 18, 2022, 3:00 AM EST - 3 years ago

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

Jan 13, 2022, 4:34 PM EST - 3 years ago

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Dec 13, 2021, 4:05 PM EST - 4 years ago

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Dec 7, 2021, 9:49 AM EST - 4 years ago

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

Nov 24, 2021, 9:20 AM EST - 4 years ago

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

skyrockets_Inc
skyrockets_Inc Sep. 16 at 6:22 PM
$BRNS Considering they have cash value of $2/share and several promising assets I'd say these levels are a GIFT. I'm adding more and more daily.
0 · Reply
andrewzoo
andrewzoo Sep. 16 at 5:05 PM
$BRNS Add at $1?
0 · Reply
DocPharm
DocPharm Sep. 11 at 4:35 PM
$BRNS adding
1 · Reply
Alorenz94
Alorenz94 Sep. 10 at 4:36 PM
$BRNS more volume today
0 · Reply
NVDAMillionaire
NVDAMillionaire Sep. 10 at 8:00 AM
$BRNS Brilliant piece that captures BRNS's situation perfectly. So if you want to update your understanding of BRNS or get to know BRNS better, this is essential reading. https://beyondspx.com/quote/BRNS/analysis/barinthus-bio-s-strategic-pivot-unlocking-immune-tolerance-potential-nasdaq-brns
0 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 9 at 4:54 PM
$BRNS
0 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 9 at 2:56 PM
$BRNS volume is still abnormally high for this stock. I still maintain something is going on behind the scenes and we are going to get a large upward movement soon!
1 · Reply
Alorenz94
Alorenz94 Sep. 9 at 12:25 PM
$BRNS char gbt commentary:
0 · Reply
DocPharm
DocPharm Sep. 8 at 6:27 PM
$BRNS adding a few over the next few days
1 · Reply
Alorenz94
Alorenz94 Sep. 5 at 8:11 PM
$BRNS somebody just bought 10-20k shares are the close
0 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 4 at 2:44 PM
$BRNS Somebody has been quietly loading in the last 3 - 4 days....interesting upward slow healthy volume. Holding solidly above the 200,100, and just crossed above the 50 SMA. Bullish signs.
2 · Reply
DocPharm
DocPharm Sep. 4 at 2:30 PM
$BRNS 🤫 ac💦ul8
0 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 3 at 2:54 PM
$BRNS Sent another email to IR and they didn't respond...however Bill Enright the CEO did. Here is my email and his response. Nothing useful. However I do find it weird that he refers to the company as 'they' instead of 'we' when talking about VTP-850. He is the CEO of course....... My email: "Is there a reason why the VTP850 data has been glossed over in the past two 10qs? I know there is a simple statement in the most recent PR stating that the trial is complete and it had ‘encouraging data’, but why is the data itself not being PR’d and released? Is this not material info? I would think the data would need to be released to shareholders by now unless you are in partnering talks/active negotiations with a 3rd party. " Bill's response: "Hi – thanks for your note. The Company has disclosed, including in its recent 10-Q, that the trial is now complete and the data will be used to facilitate partnering discussions as they do not intend to develop VTP-850 without a partner."
1 · Reply
skyrockets_Inc
skyrockets_Inc Sep. 2 at 4:26 PM
$BRNS this thing has been stable with decent volume now for almost 30 days since the big POP. I still maintain something is going on behind the scenes w/ management being so quiet. One day we're going to wake up to another large POP imo, possibly on partnership news.
0 · Reply
johnnygogogo
johnnygogogo Aug. 29 at 3:52 PM
$BRNS there’s basically no bid / ask on this. You have to guess where to put your limit order.
0 · Reply
johnnygogogo
johnnygogogo Aug. 28 at 10:03 PM
$BRNS added 8 trial sites to VTP-1000
1 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 28 at 2:45 PM
$BRNS Added 5k more shares. MANAGEMENT IS SILENT. Stopped responding to my emails, same with IR. They must be in a quiet period for VTP-850 and/or VTP-300. VTP-850 have been complete for over 3 months and they still haven't released them. That is MATERIAL. So they must be in confidential negotiations with somebody. The timing lines up perfectly w/ the mid July stock POP . I believe that was a leak that then lead to a day trade frenzy. $2/share in cash w/ one active drug VTP-100, 2 partnered drugs VTP-400 and VTP-500. And two drugs actively looking for partners (VTP-850 and 300 from above). This stock is worth $6/share at min, possibly $10 IMO. Long time tutes want out of their initial 200M investment (Oxford Life Sciences)
1 · Reply
johnnygogogo
johnnygogogo Aug. 26 at 5:37 PM
$BRNS VTP-1000 countdown is on. “Early Q4” (so anytime after Oct 1 and before November 15). MAD trials started in July and that couldn’t have happened if SAD safety were anything but pristine. If you have Celiac and you’re in this trial and on drug (vs placebo) and you are exposed to gluten, you absolutely know whether or not it is working. No options, no way to hedge. Valued below cash. Looking to partner off HBV and prostate while focus is on VTP-1000. Let’s start digging here.
1 · Reply
johnnygogogo
johnnygogogo Aug. 26 at 5:00 PM
$BRNS
0 · Reply
Tacto
Tacto Aug. 22 at 5:51 AM
$BRNS Bullish P&F 'Low Pole Reversal' today
1 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 21 at 5:21 PM
$BRNS Officially adding more shares. Loading the boat. IR has been silent the past 4 weeks and not responded ever since I asked about sale negotiations of VTP-300 / 850. They deliberately didn't release the VTP-850 data, and the stock has been trading w/ strange volume ever since the initial pump 5 weeks ago. I think we hear something in the next few weeks, $2/share in cash . I think we could be above $4. Just my opinion. LOADING MORE.
1 · Reply
skyrockets_Inc
skyrockets_Inc Aug. 20 at 4:32 PM
$BRNS One last email to IR today to ask if they are in a quiet period or not. If I don't get a response this time, will be very telling...considering they were extremely responsive at the beginning of July.
0 · Reply